Dana Investment Advisors, Inc. Uni Qure N.V. Transaction History

Dana Investment Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$14.54 - $21.5 $232,349 - $343,570	-15,980 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$20.24 - $36.01 $147,772 - $262,909	-7,301 Reduced 31.36%	15,980 $331,000
Q3 2021 Nov 12, 2021	SELL	$26.01 - $38.22 $858 - $1,261	-33 Reduced 0.14%	23,281 $745,000
Q2 2021 Aug 10, 2021	BUY	$29.97 - $37.17 $9,350 - $11,597	312 Added 1.36%	23,314 $718,000
Q1 2021 May 13, 2021	SELL	$29.24 - $42.03 $3,918 - $5,632	-134 Reduced 0.58%	23,002 $775,000
Q4 2020 Feb 11, 2021	SELL	$35.35 - $50.67 $1,378 - $1,976	-39 Reduced 0.17%	23,136 $836,000
Q3 2020 Nov 10, 2020	BUY	$35.98 - $47.66 $833,836 - $1.1 Million	23,175 New	23,175 $854,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Dana Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Dana Investment Advisors, Inc. with notifications on news.